News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 325–360
- Matches
- 584
- Sources here
- 24
- Companies here
- 13
Search results
Stored financial headlines
Active search
584 matching headlines
Ticker or company: AKAMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Price to earnings forward of Akari Therapeutics Plc Sponsored ADR – TRADEGATE:CLA1
The article displays the "Price to earnings forward" metric for Akari Therapeutics Plc Sponsored ADR (CLA1) on the Tradegate Exchange. It indicates no trades and provides an overview of financial data and community features. The page primarily serves as a financial data display for …
AKTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -74.2% · Next-week setup negative 38.1%
AKA stock trades around recent lows as revenue declines and losses widen
AKA Brands Holding Corp. (AKA) is experiencing significant market pressure, with its stock trading near recent lows due to declining revenue and widening net losses. The e-commerce group reported a reduction in net revenue from $500 million in fiscal 2022 to $400 million in …
AKA
main company
Sharemaestro market context
Trend signal started
52 weeks +0.1%
Implied Volatility Surging for Akamai Stock Options
Investors in Akamai Technologies, Inc. AKAM need to pay close attention to the stock based on moves in the options market lately. That is because the Sept. 18, 2026 $45.00 Call had some of the highest implied volatility of all equity options today. What …
Sharemaestro market context Trend signal active 52 weeks +57.7% · Next-week setup negative 43.8%Akamai (AKAM) Joins World Wide Technology’s ARMOR Framework For Enterprise AI Security
Akamai Technologies has been selected as a key security partner for World Wide Technology’s new AI Readiness Model for Operational Resilience (ARMOR) framework, which is the industry's first holistic, vendor-agnostic AI security model. This partnership positions Akamai as a foundational security layer for protecting …
Sharemaestro market context Trend signal ended 52 weeks +39.5%Akamai Technologies stock holds recent gains as security and cloud revenue support valuation
Akamai Technologies (NASDAQ: AKAM) stock has maintained recent gains, supported by strong revenue growth in its security and cloud segments, which now contribute significantly to its overall financial performance. The company reported improved margins and earnings per share in fiscal 2024, driven by a …
AKAM
main company
Sharemaestro market context
Trend signal ended
52 weeks +39.5%
Akari Therapeutics (AKTX) Proxy filing Summary
Akari Therapeutics (AKTX) has released a summary of its proxy filing for the 2026 Annual General Meeting scheduled for June 30, 2026. The meeting will address 18 resolutions covering financial, governance, compensation, and capital matters, with the Board unanimously recommending a vote in favor …
AKTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -74.2% · Next-week setup negative 38.1%
Akamai stock trades steady as security revenue grows and AI edge platform expands
Akamai Technologies (NASDAQ: AKAM) stock shows continued steady growth, driven by its expanding security and compute revenue streams, while its traditional media content delivery segment remains stable. The company's focus on high-margin security products and its emerging AI edge platform is improving profitability and …
AKAM
main company
Sharemaestro market context
Trend signal ended
52 weeks +39.5%
Akari Therapeutics (AKTX) Registration filing Summary
Akari Therapeutics' recent registration filing highlights its focus on developing next-generation antibody-drug conjugates (ADCs) for solid tumors, with lead candidate AKTX-101 in preclinical stages aiming for a Phase 1 trial by mid-2027. The company's financial position as of December 31, 2025, shows $5.2 million …
AKTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -74.2% · Next-week setup negative 38.1%
Form 4 Akari Therapeutics PLC For: 17 July By Investing.com
This article from Investing.com reports the filing of a Form 4 for Akari Therapeutics PLC. The filing is related to activity on July 17, as indicated by the title. The article provides the company's stock symbol AKTX and its current price performance.
AKTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -74.2% · Next-week setup negative 38.1%
Akari Therapeutics (AKTX) director exercises pre-funded warrants for 22,474 ADSs
Akari Therapeutics director Samir Rashmikant Patel, through PranaBio Investments LLC, exercised pre-funded warrants on July 7, 2026, to acquire 22,474 American Depositary Shares (ADSs). These exercises involved different price points ($0.0004 and $8.00 per ADS) and were not part of a Rule 10b5-1 trading …
AKTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -74.2% · Next-week setup negative 38.1%
Akamai Technologies stock trades steadily as security and cloud growth support earnings
Akamai Technologies' stock reflects stable performance, driven by strong growth in its edge security and cloud computing segments. The company reported significant revenue and earnings growth in fiscal 2024, with security solutions being the largest contributor. Akamai's financial health is further supported by robust …
AKAM
main company
Sharemaestro market context
Trend signal ended
52 weeks +39.5%
Akamai Technologies, Inc. Stock 12‑Month Price Target Raised to $161.19, Implies 34% Upside
Akamai Technologies, Inc. (AKAM) has seen its average 12-month price target raised to $161.19 by 21 analysts, suggesting a 34% potential upside from its July 15th closing price. The consensus analyst rating remains a "Buy" among 28 covering analysts, with the majority recommending a …
AKAM
main company
Sharemaestro market context
Trend signal ended
52 weeks +39.5%
Akari Therapeutics (AKTX) Q1 2026 earnings summary
Akari Therapeutics (AKTX) reported a Q1 2026 net loss of $14.5 million, significantly higher than Q1 2025 due to non-cash impairment charges. The company is focused on advancing its lead ADC program, AKTX-101, towards a Phase 1 trial by mid-2027 but faces substantial doubt …
AKTX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -74.2% · Next-week setup negative 38.1%
Akamai Technologies Inc (AKAM) Stock Down 4.8% but Still Overvalued
Akamai Technologies Inc (AKAM) shares dropped 4.8% to $120.01 but are still considered overvalued, trading 7.0% above its GF Value™ of $112.21. The GF Score™ of 84/100 indicates strong growth and profitability, though momentum and financial strength are moderate. Insider selling activity, totaling $0.3 …
AKAM
main company
Sharemaestro market context
Trend signal ended
52 weeks +39.5%
Akamai Technologies EVP Joseph Paul C sells $392,987 in stock
Akamai Technologies' Executive Vice President of Global Sales, Joseph Paul C, sold 3,100 shares of company stock for $392,987 on July 15, 2026, under a Rule 10b5-1 trading plan. Despite a 64% return over the past year, the company's stock currently trades below the …
AKAM
main company
Sharemaestro market context
Trend signal ended
52 weeks +39.5%
Form 4 Akamai Technologies Inc For: 15 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Akamai Technologies Inc. (AKAM) on July 15. The content indicates standard financial reporting for the company. There are no specific details provided about the nature of the Form 4 filing itself within the …
AKAM
main company
Sharemaestro market context
Trend signal ended
52 weeks +39.5%
Akamai Technologies (NASDAQ: AKAM) EVP sells 3,100 shares under plan
Akamai Technologies' EVP - Global Sales, Joseph Paul C, reported an open-market sale of 3,100 common shares of AKAM on July 15, 2026, at $126.77 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted on March 4, 2026. Following the …
AKAM
main company
Sharemaestro market context
Trend signal ended
52 weeks +39.5%
Akamai Technologies (NASDAQ: AKAM) holder to sell 6,200 common shares
A holder of Akamai Technologies (NASDAQ: AKAM) plans to sell up to 6,200 common shares with an aggregate market value of $785,974.00 on July 15, 2026. These shares are held through Charles Schwab & Co., Inc. and originate from equity compensation awards, including Performance …
AKAM
main company
Sharemaestro market context
Trend signal ended
52 weeks +39.5%
Akamai jumps to No. 3 in Infrastructure Software while activity pressure turns negative
AKAM rose 11.5% to $126.20 in the week to 10 July, restoring distance above its Trend Line, but the move arrived on below-average 13-week volume and a negative Market Dynamics read.
AKAM
main company
Sharemaestro market context
Trend signal ended
52 weeks +39.5%